If you wish to receive all of the company’s financial communications in real time, you can register directly by email at the following address: [email protected]
ERYTECH Pharma (Euronext Paris and Nasdaq: ERYP), a clinical-stage biopharmaceutical company that develops innovative therapies by encapsulating drugs in red blood cells, announces that Akkadian Partners has initiated a procedure aimed at obtaining the postponement of the vote at the General Meeting on June 23 of the merger with Pherecydes.
Erytech intends to obtain the dismissal of this legal action, which it considers to be unfounded, and thus allow its shareholders to vote on the merger with Pherecydes on June 23.